Mieczyslaw L.
- Country
- Poland
- Department
- Klinika Nefrologii, Transplantacji Nerek i Nadcisnienia Tetniczego
Research Overview
- Safety, Tolerability, and Efficacy of Tolvaptan in Pediatric Patients with Autosomal Recessive Polycystic Kidney Disease: A Phase 3b Multicenter Open-label Trial
- Phase 3b Multicenter Open-label Study on Tolvaptan's Safety, Tolerability, and Efficacy in Infants with Autosomal Recessive Polycystic Kidney Disease
- Evaluation of Finerenone in Combination with ACEI or ARB for Proteinuria and Chronic Kidney Disease in Pediatric Patients: A Randomized, Double-Blind, Placebo-Controlled Trial
Data & Insights
Has run more than one trial at 28 of 80 partner sites.
Specializations
Pediatric Kidney Disorders
The investigator specializes in treating various forms of pediatric kidney diseases, with particular emphasis on Autosomal Recessive Polycystic Kidney Disease (ARPKD) in infants and children.
- Early-onset kidney disorders
- Developmental kidney conditions
- Inherited renal diseases
Their work extends to evaluating therapeutic interventions for children from newborn to adolescent age groups.
Chronic Kidney Conditions
Focus areas include the treatment of chronic kidney disease complicated by proteinuria in pediatric patients, exploring innovative therapeutic approaches.
- Protein excretion disorders
- Long-term kidney disease management
- Renal protection strategies
The investigator works with various therapeutic agents to address kidney dysfunction in young patients.
Glomerular Diseases
Expertise in treating various proteinuric glomerular diseases, including complex conditions such as focal segmental glomerulosclerosis and Alport syndrome.
- IgA nephropathy
- Minimal change disease
- IgA vasculitis
Their research encompasses rare kidney disorders and innovative treatment approaches for pediatric patients.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.